Potential New Target Identified in Triple-Negative Breast Cancer

Potential New Target Identified in Triple-Negative Breast Cancer

A subset of triple-negative breast cancers contains a genetic change that contributes to cancer growth and may be possible to target with drugs. These results were published in Nature.

Targeted therapies are anticancer drugs that interfere with specific pathways involved in cancer cell growth or survival. Some targeted therapies block growth signals from reaching cancer cells, others reduce the blood supply to cancer cells, and still others stimulate the immune system to recognize and attack the cancer cells. Depending on the specific “target,” targeted therapies may slow cancer cell growth or increase cancer cell death.

In order to identify targeted therapies that may be effective for a particular type of cancer, it’s important to understand the factors that drive the cancer. A study recently published in the journal Nature sought to identify genetic changes that may contribute to certain types of breast cancer, including triple-negative breast cancer. The study collected tumor samples from 103 breast cancer patients fromMexico andVietnam. The DNA from the tumor samples was compared with DNA from normal tissue.

A genetic change that was identified in a triple-negative sample involved a fusion of two genes: MAGI3 and AKT3. The protein produced by this fusion gene is thought to contribute to cancer growth. When the researchers looked for this fusion gene in another set of tumor samples, they found it in 7% of triple-negative samples (5 out of 72).

Drugs that target this biological pathway are already being investigated for other purposes, and may eventually prove to be useful for triple-negative breast cancers that contain the fusion gene. If researchers are able to find a targeted drug that is effective against these cancers, it would be an important advance in the treatment of triple-negative breast cancer. Only a subset of triple-negative breast cancers contain the genetic change identified in this study, but ongoing research may identify additional targets.

Reference: Banerji S, Cibulskis K, Rangel-Escareno C et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature;2012;486:405-409.

Copyright © 2018 CancerConnect. All Rights Reserved.

Comments (1)
No. 1-1
mary john
mary john

ALL THANKS TO DR OSO WITH HIS HERBAL PORTION I WAS COMPLETELY CURED FROM BREAST CANCER. I’m here again to appreciate. DR OSO God will always continue to bless you more abundantly, for the good works you don in my life, I will always keep on writing good and posting my testimonies about you on the Internet, I’m MARY JOHNSON from TEXAS . I was tested breast cancer positive, I saw a blog on how DR OSO cured people with his herbal portion, i did not believe in natural medicine but i just decided to give him a try, I contacted him,and explain my situation to him,few day later he sent me the herb, after taking DR OSO herbal medicine for few weeks i went to hospital for check up so luckily i was healed with his herbal portion, i am so happy. If you have any type of cancer problem or you are also infected with any kind of disease, contact him drosohaberhome@gmail.com or call/whatapp +2348162084839 for advice and for his product,i hope this testimony also help some one out there .. here is the dr website. https://sites.google.com/view/drosohaberhome/ His blog page https://drosohaberhome.blogspot.com you can also email me for more info about DR oso via maryjohnson9700@gmail.com ALL THANK TO DR OSO... ...........................//